X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (222) 222
life sciences & biomedicine (216) 216
humans (206) 206
oncology (186) 186
male (106) 106
respiratory system (100) 100
female (98) 98
lung neoplasms - pathology (94) 94
middle aged (93) 93
aged (91) 91
lung neoplasms - drug therapy (78) 78
lung cancer (74) 74
carcinoma, non-small-cell lung - drug therapy (68) 68
adult (66) 66
carcinoma, non-small-cell lung - pathology (58) 58
neoplasm staging (58) 58
pulmonary and respiratory medicine (50) 50
prognosis (48) 48
treatment outcome (45) 45
aged, 80 and over (44) 44
lung cancer, non-small cell (44) 44
chemotherapy (42) 42
cancer (40) 40
antineoplastic combined chemotherapy protocols - therapeutic use (36) 36
care and treatment (34) 34
lung neoplasms - diagnostic imaging (34) 34
non-small cell lung cancer (34) 34
lung neoplasms - mortality (33) 33
carcinoma, non-small-cell lung - mortality (28) 28
nsclc (26) 26
lung neoplasms - therapy (25) 25
staging (25) 25
survival rate (25) 25
antineoplastic agents - therapeutic use (24) 24
cisplatin - administration & dosage (24) 24
darbepoetin alfa (24) 24
anemia - drug therapy (22) 22
antineoplastic agents - adverse effects (22) 22
carcinoma, non-small-cell lung - diagnostic imaging (22) 22
non-small cell lung carcinoma (22) 22
research (22) 22
survival analysis (22) 22
prospective studies (21) 21
randomized controlled trials as topic (21) 21
carcinoma, non-small-cell lung - genetics (20) 20
clinical trials (20) 20
erythropoietin - analogs & derivatives (20) 20
hematology, oncology and palliative medicine (20) 20
lymphatic metastasis (20) 20
lung neoplasms - genetics (19) 19
lung neoplasms - surgery (19) 19
anemia - chemically induced (18) 18
carcinoma, non-small-cell lung - therapy (18) 18
disease-free survival (18) 18
fluorodeoxyglucose f18 (18) 18
tomography, x-ray computed (18) 18
double-blind method (17) 17
lung neoplasms - classification (17) 17
quality of life (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
cancer therapies (16) 16
immunotherapy (16) 16
lung neoplasms - diagnosis (16) 16
pemetrexed (16) 16
radiopharmaceuticals (16) 16
retrospective studies (16) 16
surgery (16) 16
tumors (16) 16
abridged index medicus (15) 15
analysis (15) 15
carcinoma, non-small-cell lung - surgery (15) 15
diagnosis (15) 15
metastasis (15) 15
mutation (15) 15
non-small-cell lung cancer (15) 15
anemia (14) 14
erythropoietin - therapeutic use (14) 14
neoplasm staging - methods (14) 14
neoplasms - drug therapy (14) 14
patients (14) 14
drug administration schedule (13) 13
general & internal medicine (13) 13
health aspects (13) 13
human medicine (13) 13
positron-emission tomography (13) 13
survival (13) 13
combined modality therapy (12) 12
drug therapy (12) 12
guanine - analogs & derivatives (12) 12
lung neoplasms - immunology (12) 12
lung neoplasms - radiotherapy (12) 12
radiology, nuclear medicine & medical imaging (12) 12
respiratory tract diseases (12) 12
carcinoma, non-small-cell lung - secondary (11) 11
chemotherapy, adjuvant (11) 11
clinical trials as topic (11) 11
erbb receptors - genetics (11) 11
lymph nodes - pathology (11) 11
review (11) 11
sensitivity and specificity (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 04/2016, Volume 387, Issue 10030, pp. 1837 - 1846
Journal Article
The lancet oncology, ISSN 1470-2045, 06/2016, Volume 17, Issue 6, pp. 822 - 835
Journal Article
The lancet oncology, ISSN 1470-2045, 01/2013, Volume 14, Issue 1, pp. 38 - 47
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2018, Volume 379, Issue 24, pp. 2342 - 2350
Journal Article
Journal of thoracic oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S125 - S127
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2020, Volume 382, Issue 1, pp. 41 - 50
Osimertinib was compared with standard EGFR blockers among patients with non–small-cell lung cancer with activating mutations in EGFR . The median overall... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Female | Lung Neoplasms - genetics | ErbB Receptors - antagonists & inhibitors | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Gefitinib - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - therapeutic use | Acrylamides - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Aniline Compounds - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Tyrosine | Cell survival | Statistical analysis | Epidermal growth factor receptors | Small cell lung carcinoma | Non-small cell lung carcinoma | Metastasis | Gene deletion | Confidence intervals | Epidermal growth factor | Clonal deletion | Clinical medicine | Gefitinib | Protein-tyrosine kinase | Drug dosages | Cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article